JASON VESTAL: Open Payments
NPI 1851899215 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$174 in 7 payments from 7 companies in 2025. Trend: 2023 $495 · 2024 $174 · 2025 $174
Food & beverage: $174
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 1 | $43 |
| Alkermes, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Janssen Pharmaceuticals, Inc | 1 | $22 |
| ABBVIE INC. | 1 | $18 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
Products named: UZEDY, ARISTADA, CAPLYTA, REXULTI, INVEGA SUSTENNA, VRAYLAR, COBENFY.
Industry payments across WA — which companies pay providers there.
